Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MET | P08581 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5499989 | 1.00 | KDM4E (0.57) | KDM4ESMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL5567501 | 0.91 | KDM4E (0.64) | KDM4ESMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL361837 | 0.91 | KDM4E (0.58) | KDM4ESMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL7526518 | 0.91 | KDM4E (0.64) | KDM4ESMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL2927309 | 0.91 | ALDH1A1 (0.54) | KDM4ESMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL3284414 | 0.90 | SMN1; SMN2 (0.57) | KDM4ESMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL28341714 | 0.90 | SMN1; SMN2 (0.57) | KDM4ESMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL27958219 | 0.88 | CYP2D6 (0.66) | KDM4ESMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL3709691 | 0.87 | ALDH1A1 (0.57) | KDM4ESMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL3527664 | 0.87 | ALDH1A1 (0.57) | KDM4ESMN1; SMN2ALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110747489-B | Electroreduction preparation method of intermediate of anticancer drug gefitinib and analogue thereof | 湖南大学 | 2021-05-07 | — | — | CN | disclosed |
| CN-110747489-A | Electroreduction preparation method of intermediate of anticancer drug gefitinib and analogue thereof | 湖南大学 | 2020-02-04 | — | — | CN | disclosed |
| US-8350029-B2 | Process for the preparation of gefitinib | CIPLA LIMITED (IN) | 2013-01-08 | — | — | US | disclosed |
| US-8350029-B2 | Process for the preparation of gefitinib | CIPLA LIMITED (IN) | 2013-01-08 | — | — | US | disclosed |
| US-20100137586-A1 | Process for the Preparation of Gefitinib | CIPLA LIMITED (IN) | 2010-06-03 | — | — | US | disclosed |
| US-20100137586-A1 | Process for the Preparation of Gefitinib | CIPLA LIMITED (IN) | 2010-06-03 | — | — | US | disclosed |
| WO-2005070909-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF GEFITINIB | NATCO PHARMA LIMITED (IN) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137586-A1 | Process for the Preparation of Gefitinib | EGFR, BRAF, KRAS | KDM4E 1987/4885SMN1; SMN2 4673/4885ALDH1A1 2730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.